Navigation Links
Diatos Announces Positive Clinical Results for its DTS-201,Doxorubicin Prodrug Program

or tumor selective drug delivery. The DTS-201 concept is based on the inactivation of doxorubicin by the coupling of a tetrapeptidic sequence that prevents cellular uptake. DTS-201 is stable in blood but cleavable by some specific peptidases present in the tumor environment. Preclinical studies have demonstrated that DTS-201 was less toxic in rodents and dogs than free doxorubicin and significantly more effective in a wide panel of human tumor xenograft models.

Reactivation of doxorubicin occurs extracellularly in the tumor through enzymatic cleavage of the peptide by at least two enzymes: CD10 (Neprilysin / CALLA) and Thimet Oligopeptidase (TOP). They produce two intermediate metabolites Ala-Leu-Dox and Leu-Dox which enter stromal and tumor cells and are converted into free doxorubicin.

About Diatos

Diatos is a biopharmaceutical company dedicated to the research, development and commercialization of innovative anti-cancer drugs with enhanced tumor targeting or improved biodistribution. Diatos is expanding its portfolio of drug candidates with new compounds that utilize its Vectocell(R) delivery technology or its Tumor-Selective Prodrug (TSP) technology as well as with in-licensed candidate and marketed cancer therapies. Diatos is headquartered in Paris, France and operates subsidiaries in Belgium and the United States of America.

About Diatos' Portfolio

-- DaunoXome(R), a liposomal formulation of widely used cancer drug daunorubicin, improves the biodistribution of daunorubicin and fosters its sustained release in the blood, which potentially allows the administration of higher doses than with non-liposomal formulations. DaunoXome is marketed in Kaposi's sarcoma and under review for the treatment of acute leukaemia in Europe. DaunoXome was in-licensed from Gilead Sciences, Inc. (NASDAQ: GILD).

-- DTS-301, a paclitaxel depot formulation in the polymer gel ReGel(R), releases paclitaxel, a widely used cancer drug, directly to
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
4. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
5. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
11. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
Post Your Comments:
(Date:5/15/2008)... - Unprecedented amount of research reflects ...ators worldwide to develop new treatments for ...nary session to highlight impact of Zometa(R), the...tients with early-stage breast cancer, - Four ora...y continuous, inhibitor of mTOR, including first r...
(Date:5/15/2008)... Excellent results obtained with a newly cleared...ary plaques of interest that are associated with ...g, BURLINGTON, Mass., May 15 /- Infr...umont Hospital in Royal Oak, Mich., have,successfu...in a patient,undergoing a cardiac catheterization....
(Date:5/15/2008)... BONITA SPRINGS, Fla., May 15 /- T...ecution of a Cooperative Research and,Development ...te (NCI) to,collaborate on clinical and preclinica...y in Phase I development. AFP-464 is converted to,...g in p53 activation and,apoptosis., This is part ...
(Date:5/15/2008)...- Top Line Data Expected soon after CEA Trial data... -, SAN FRANCISCO, May 15 /PRNewswire-Fi...AP ), a biotechnology company focused on the devel...cular disease, announced today that,it has complet...me (ACS),study. The ACS study is one of three Phas...
Breaking Medicine Technology:Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 2Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 3Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 4Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 5Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 6Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 7Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 8Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 9Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 10First Use in a Patient of The InfraReDx LipiScan(TM) Coronary Imaging System 2First Use in a Patient of The InfraReDx LipiScan(TM) Coronary Imaging System 3First Use in a Patient of The InfraReDx LipiScan(TM) Coronary Imaging System 4Tigris Pharmaceuticals Signs CRADA with the National Cancer Institute 2Tigris Pharmaceuticals Signs CRADA with the National Cancer Institute 3VIA Pharmaceuticals Completes Enrollment in Phase 2 Acute Coronary Syndrome (ACS) Trial 2VIA Pharmaceuticals Completes Enrollment in Phase 2 Acute Coronary Syndrome (ACS) Trial 3VIA Pharmaceuticals Completes Enrollment in Phase 2 Acute Coronary Syndrome (ACS) Trial 4VIA Pharmaceuticals Completes Enrollment in Phase 2 Acute Coronary Syndrome (ACS) Trial 5PA Soldiers and Sailors Home Dedicates 32 Bed Dementia Alzheimers Unit 773 1Rain Man mice provide model for autism 771 1Rain Man mice provide model for autism 771 2An Innovation in Health Care Opens at a CVS pharmacy Store in the Oklahoma City Region 766 1An Innovation in Health Care Opens at a CVS pharmacy Store in the Oklahoma City Region 766 2An Innovation in Health Care Opens at a CVS pharmacy Store in the Oklahoma City Region 766 3An Innovation in Health Care Opens at a CVS pharmacy Store in the Oklahoma City Region 766 4An Innovation in Health Care Opens at a CVS pharmacy Store in the Oklahoma City Region 766 5Wyeth Sets Webcast and Conference Call for 2007 Third Quarter Earnings 435 1
... , GENEVA, Switzerland, April 27, 2007 –,Me...on,Pharmaceuticals S.p.A. (SWX: NWRN) announced to... present the results of the first,Phase III trial ...ne agonists (DA) in early Parkinson’s diseas...gy 59th Annual Meeting,to be held in Boston from 2...
...IRVINE, Calif.--(BUSINESS WIRE)--Apr 30, 2007 - Co...opment company specializing in,anti-allergy medica... independent contract research organization that i...ocked data bases into a single,database before un-...equired to generate top-line results for Cobalis, ...
Other Medicine Technology:Merck Serono Announces Presentation of Phase III Clinical Data on,Safinamide in Parkinson’s Disease at the American Academy of,Neurology 59th Annual Meeting 2Merck Serono Announces Presentation of Phase III Clinical Data on,Safinamide in Parkinson’s Disease at the American Academy of,Neurology 59th Annual Meeting 3Merck Serono Announces Presentation of Phase III Clinical Data on,Safinamide in Parkinson’s Disease at the American Academy of,Neurology 59th Annual Meeting 4Cobalis Expects to Report Phase III Top-Line Results in May 2
(Date:5/16/2008)...ffices of Howard G. Smith,announces a June 9, 2008...ecurities class action lawsuit filed on behalf of ...e common stock of Inverness Medical,Innovations, I... IMA ) in the,Company,s secondary public offering .... The shareholder lawsuit is pending in the United...
(Date:5/16/2008)...s want agency to act, not wait years , ,...umer drug ads on television should include a toll-...port adverse side effects, U.S. health experts sug...hat advises the U.S. Food and Drug Administration....A for print ads. At Friday,s meeting, the panel di...
(Date:5/16/2008)...HINGTON, May 16 /PRNewswire-USNewswire/ -- More th...s in the Greater Portland, Oregon and,Vancouver, W...ract as,Teamsters., "The Teamsters are pleased th...act that gives them job protection and a secure re... Jim Hoffa., The workers, both full-time and part...
(Date:5/16/2008)...fit from calcitriol, an oral form , , FR...vitamin D may cut the risk of death for people wit...ut one quarter, a new study suggests. , During...se being treated with calcitriol, an oral form of ...th lowered by 26 percent when compared with those ...
Breaking Medicine News(10 mins):Health News:Law Offices of Howard G. Smith Announces 24 Days Remaining to Move to Be a Lead Plaintiff in the Shareholder Lawsuit Against Inverness Medical Innovations, Inc. 2Health News:FDA Panel Considers Toll-Free Number for TV Drug Ads 2Health News:FDA Panel Considers Toll-Free Number for TV Drug Ads 3Health News:Vitamin D Use Linked to Lower Mortality in Kidney Patients 2
...the British Government would be conducting a separ...nsultant radiologist in Ireland. // These clinical... scanner and have necessitated the recall of close...ir breast cancer examinations. The enquiry team w...
...ries is in the threat of ban on their export of se...food from Asian countries had the banned chemical ...el that the Canadian Food Inspection Agency should...d test all batches of imported seafood coming into...
... was brought home in a very uncomfortable manner w...e of the greatest footballers' died in London yest...after his own liver failed in the aftermath of his...case. Millions of people the world over, mostly ma...
...-1) is required for both cartilage and bone growth...d by the pituitary gland.// Deficiency of IGF-1 re...tabolic abnormalities including insulin resistance...IGF-1 drugs helps in production of IGF-1 in childr...
Other Medicine News:
...aboratories is a national reference laboratory and...rch and development. ARUP offers an extensive test...n clinical and anatomic pathology. Owned by the Un...de more than half of the nation's university teach...
...aboratories is a national reference laboratory and...rch and development. ARUP offers an extensive test...n clinical and anatomic pathology. Owned by the Un...de more than half of the nation's university teach...
...aboratories is a national reference laboratory and...rch and development. ARUP offers an extensive test...n clinical and anatomic pathology. Owned by the Un...de more than half of the nation's university teach...
...aboratories is a national reference laboratory and...rch and development. ARUP offers an extensive test...n clinical and anatomic pathology. Owned by the Un...de more than half of the nation's university teach...
Medicine Products: